Thiarabine shows promise for rheumatoid arthritis
Access Pharmaceuticals, Inc. announced today new preclinical data demonstrating that thiarabine shows remarkable efficacy in the prevention and treatment of rheumatoid arthritis (RA).
Thiarabine is a next generation nucleoside analogue that Access has licensed from Southern Research. It has been in two Phase 1/2 solid tumor trials and was shown to have significant anti-tumor activity. Access is now working with leukemia and lymphoma specialists to initiate additional Phase 2 clinical trials in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and other indications. “The IND for thiarabine has been transferred to Access and we have a supply of clinical-grade material.” commented Dr. Nowotnik, Senior Vice President Research and Development. “We should be able to start the study shortly after FDA clearance of the protocol and drug recertification.”
